N-[6-(1-methyltriazol-4-yl)isoquinolin-3-yl]-2-(1-propan-2-ylpiperidin-4-yl)-1,3-oxazole-4-carboxamide
C24H27N7O2 — CID 138585612
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[6-(1-methyltriazol-4-yl)isoquinolin-3-yl]-2-(1-propan-2-ylpiperidin-4-yl)-1,3-oxazole-4-carboxamide
N-[6-(1-methyltriazol-4-yl)isoquinolin-3-yl]-2-(1-propan-2-ylpiperidin-4-yl)-1,3-oxazole-4-carboxamide (PubChem CID 138585612) has the molecular formula C24H27N7O2 and a molecular weight of 445.53 g/mol. Its IUPAC name is N-[6-(1-methyltriazol-4-yl)isoquinolin-3-yl]-2-(1-propan-2-ylpiperidin-4-yl)-1,3-oxazole-4-carboxamide.
Molecular Properties
| Compound Name | N-[6-(1-methyltriazol-4-yl)isoquinolin-3-yl]-2-(1-propan-2-ylpiperidin-4-yl)-1,3-oxazole-4-carboxamide |
|---|---|
| PubChem CID | 138585612 |
| Molecular Formula | C24H27N7O2 |
| Molecular Weight | 445.53 g/mol |
| Exact Mass | 445.22 |
| IUPAC Name | N-[6-(1-methyltriazol-4-yl)isoquinolin-3-yl]-2-(1-propan-2-ylpiperidin-4-yl)-1,3-oxazole-4-carboxamide |
| SMILES | CC(C)N1CCC(c2nc(C(=O)Nc3cc4cc(-c5cn(C)nn5)ccc4cn3)co2)CC1 |
| InChI | InChI=1S/C24H27N7O2/c1-15(2)31-8-6-16(7-9-31)24-26-21(14-33-24)23(32)27-22-11-19-10-17(4-5-18(19)12-25-22)20-13-30(3)29-28-20/h4-5,10-16H,6-9H2,1-3H3,(H,25,27,32) |
| InChIKey | GRZXIYSOIUKKAZ-UHFFFAOYSA-N |
| XLogP | 3.86 |
| TPSA | 101.97 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 445.53 |
| LogP ≤ 5 | 3.86 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 138585612 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.